title: Prognostic factors in disseminated prostatic cancer, with special emphasis on extent of disease.
abstract: Current clinical trials in disseminated prostatic cancer mostly use M0 or M1 to identify two prognostically different groups of patients. Soloway et al. [Cancer 1988;61:195-202] have shown a significant difference in survival depending on the extent of disease (EOD) on bone scan in M1 disease. Seventy-three prostatic cancer patients with bone-scan-proven metastases (T0-4 Nx M1 G1-3) from the Aust-Agder County in Norway with observation time 2-9 years were followed. The impact of T stage, grade, serum acid phosphatase status and EOD on survival was analyzed. EOD was assessed according to Soloway et al. No statistically significant difference could be demonstrated according to T stage or histological grade. A statistically significant difference in survival could be demonstrated both for normal versus elevated serum acid phosphatase and for EOD. EOD I/II had a better prognosis than EOD III/IV. Stratification of patients in EOD categories seems relevant, but the relative importance of the different EOD categories is not yet established.
authors.affiliation: Department of Surgery, Aust-Agder Central Hospital, Arendal, Norway.
authors.forename: G
authors.initials: G
authors.lastname: Waaler
authors.forename: M O
authors.initials: MO
authors.lastname: Nilssen
mesh_terms: D000135:Acid Phosphatase / Q000097:blood; D000368:Aged; D001859:Bone Neoplasms / Q000401:mortality / Q000556:secondary*; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000401:mortality* / Q000473:pathology; D012307:Risk Factors; D016019:Survival Analysis; D015996:Survival Rate
chemical_list: D000135:Acid Phosphatase